Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HO-3
- Development stage
- Preclinical
- Lead developer
- Trion Research
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HO-3 is a murine IgG2a monoclonal antibody developed by Trion Research that specifically targets the epithelial cell adhesion molecule (EpCAM). HO-3 binds to a discontinuous epitope within the extracellular domain (specifically EGF-like domain I) of EpCAM, independent of its glycosylation status. It serves as the EpCAM-binding arm of the trifunctional bispecific antibody catumaxomab (Removab), which recruits T cells via CD3 and accessory cells via Fcγ receptors to eradicate EpCAM-positive tumor cells. HO-3 has been characterized preclinically for its high-affinity binding to EpCAM and its potential in cancer immunotherapy.
- Other names
- HO-3-19HO3-19HO 3-19clone HO-3clone HO-3-19
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on HO-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HO-3.